News

Johnson & Johnson (JNJ) reported $22.52 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 5.3%. EPS of $2.04 for the same period compares to $2.29 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $22.51 billion, representing a surprise of +0.06%. The company delivered an EPS surprise of +2.00%, with the consensus EPS estimate being $2.00.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Sales Growth (Operational growth): 6.7% versus 5.9% estimated by three analysts on average.
• Sales- Innovative Medicine- Oncology- CARVYKTI- WW: $334 million versus the four-analyst average estimate of $330.64 million. The reported number represents a year-over-year change of +110.1%.
• Sales- MedTech- Cardiovascular- ABIOMED- WW: $384 million versus $381.25 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.9% change.
• Sales- MedTech- Cardiovascular- Other Cardiovascular- WW: $99 million versus $92.29 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.2% change.
• Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW: $297 million versus $296.88 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +44.2% change.
• Sales- MedTech- Total: $8.19 billion versus $8.25 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.7% change.
• Sales- Innovative Medicine- WW: $14.33 billion compared to the $14.27 billion average estimate based on five analysts. The reported number represents a change of +4.5% year over year.
• Sales- MedTech- Orthopaedics- Trauma- WW: $764 million versus the four-analyst average estimate of $764.68 million. The reported number represents a year-over-year change of +3.1%.
• Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW: $735 million versus the four-analyst average estimate of $741.19 million. The reported number represents a year-over-year change of -0.9%.
• Sales- MedTech- Surgery- Advanced- WW: $1.15 billion compared to the $1.15 billion average estimate based on four analysts. The reported number represents a change of -1.4% year over year.
• Sales- MedTech- Surgery- WW: $2.51 billion compared to the $2.56 billion average estimate based on four analysts. The reported number represents a change of -0.9% year over year.
• Sales- Innovative Medicine- Oncology- IMBRUVICA- WW: $731 million versus the four-analyst average estimate of $729.18 million.

View all Key Company Metrics for Johnson & Johnson here>>>

Shares of Johnson & Johnson have returned +1.6% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.